Cargando…

Oncogenic activation of ERG: A predominant mechanism in prostate cancer

Prevalent gene fusions involving regulatory sequences of the androgen receptor (AR) regulated genes (primarily TMPRSS2) and protein coding sequences of nuclear transcription factors of the ETS gene family (predominantly ERG) result in unscheduled androgen dependent ERG expression in prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sreenath, Taduru L, Dobi, Albert, Petrovics, Gyorgy, Srivastava, Shiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263025/ https://www.ncbi.nlm.nih.gov/pubmed/22279422 http://dx.doi.org/10.4103/1477-3163.91122

Ejemplares similares

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1
por: Kumar, Parameet, et al.
Publicado: (2016)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India
por: Rawal, Sudhir, et al.
Publicado: (2013)

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN
por: Li, Hua, et al.
Publicado: (2015)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2019)

Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody
por: Mohamed, Ahmed A., et al.
Publicado: (2010)

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag
por: Rastogi, Anshu, et al.
Publicado: (2016)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men
por: Baohong, Jiang, et al.
Publicado: (2019)

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
por: Kohaar, Indu, et al.
Publicado: (2019)

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer
por: Xiao, Qingyu, et al.
Publicado: (2018)

Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities
por: Tan, Shyh-Han, et al.
Publicado: (2018)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
por: Dubovenko, Alexey, et al.
Publicado: (2015)

New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives
por: Eldhose, Binil, et al.
Publicado: (2021)

ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
por: Sreenath, Taduru L., et al.
Publicado: (2017)

Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
por: Sreenath, Taduru L., et al.
Publicado: (2017)

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods
por: He, Jintang, et al.
Publicado: (2015)

Prostate cancer gene expression signature of patients with high body mass index
por: Sharad, Shashwat, et al.
Publicado: (2010)

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men
por: Duncan, Allison, et al.
Publicado: (2023)

Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men
por: Farrell, James, et al.
Publicado: (2013)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Prostate cancer marker panel with single cell sensitivity in urine
por: Nickens, Kristen P., et al.
Publicado: (2015)

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence
por: Yan, Wusheng, et al.
Publicado: (2019)

The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer
por: Khosh Kish, Ealia, et al.
Publicado: (2022)

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2014)

TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence
por: Fang, Lei, et al.
Publicado: (2022)

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer
por: Urbinati, Giorgia, et al.
Publicado: (2015)

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer
por: Li, Ling, et al.
Publicado: (2020)

Biomarkers of Aggressive Prostate Cancer at Diagnosis
por: Boehm, Brock E., et al.
Publicado: (2023)

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression
por: Gao, Yuqian, et al.
Publicado: (2020)

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
por: Zoma, Marita, et al.
Publicado: (2021)

SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG
por: Shoag, Jonathan, et al.
Publicado: (2017)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation
por: Schulz, Wolfgang A, et al.
Publicado: (2010)

Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis
por: Ding, Donglin, et al.
Publicado: (2023)

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer
por: Yun, Jae Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r5phpjjga4cf3g787hpa8rfh6k